Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 35(23): 3041-3049, 2017 05 25.
Article in English | MEDLINE | ID: mdl-28465097

ABSTRACT

Post-authorisation safety studies (PASS) of vaccines assess or quantify the risk of adverse events following immunisation that were not identified or could not be estimated pre-licensure. The aim of this perspective paper is to describe the authors' experience in the design and conduct of twelve PASS that contributed to the evaluation of the benefit-risk of vaccines in real-world settings. We describe challenges and learnings from selected PASS of rotavirus, malaria, influenza, human papillomavirus and measles-mumps-rubella-varicella vaccines that assessed or identified potential or theoretical risks, which may lead to changes to risk management plans and/or to label updates. Study settings include the use of large healthcare databases and de novo data collection. PASS methodology is influenced by the background incidence of the outcome of interest, vaccine uptake, availability and quality of data sources, identification of the at-risk population and of suitable comparators, availability of validated case definitions, and the frequent need for case ascertainment in large databases. Challenges include the requirement for valid exposure and outcome data, identification of, and access to, adequate data sources, and mitigating limitations including bias and confounding. Assessing feasibility is becoming a key step to confirm that study objectives can be met in a timely manner. PASS provide critical information for regulators, public health agencies, vaccine manufacturers and ultimately, individuals. Collaborative approaches and synergistic efforts between vaccine manufacturers and key stakeholders, such as regulatory and public health agencies, are needed to facilitate access to data, and to drive optimal study design and implementation, with the aim of generating robust evidence.


Subject(s)
Adverse Drug Reaction Reporting Systems , Drug Industry/legislation & jurisprudence , Technology, Pharmaceutical/legislation & jurisprudence , Vaccines/adverse effects , Chickenpox Vaccine/adverse effects , Humans , Influenza Vaccines/adverse effects , Malaria Vaccines/adverse effects , Measles-Mumps-Rubella Vaccine/adverse effects , Papillomavirus Vaccines/adverse effects , Risk Assessment , Rotavirus Vaccines/adverse effects , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/organization & administration , Vaccination , Vaccines/administration & dosage , Vaccines, Attenuated , Vaccines, Combined/adverse effects
2.
Microb Pathog ; 35(6): 243-58, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14580388

ABSTRACT

The Ysc-Yop type III secretion (TTS) system allows extracellular Yersinia bacteria, adhering to eukaryotic target cells, to inject Yop effector proteins in the cytosol of these cells. The secretion apparatus, called the injectisome, ends up with a needle-like structure made of YscF. YopN, one of the proteins secreted by the injectisome is thought to act as a plug. YopB, YopD and LcrV, three other proteins secreted by the injectisome and called 'translocators' form a pore allowing translocation of the Yop effectors across the target cell plasma membrane. Here, we tested the role of LcrV, YscF and YopN in the formation of this pore in macrophages by monitoring the release of the low-molecular-weight fluorescent dye BCECF (2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester, 623Da) and of the high-molecular-weight lactate dehydrogenase (LDH, 135 kDa). BCECF is released through the translocation pore itself provided no Yop effector is trafficking through the channel. In contrast, LDH is released by the osmotic lysis of the target cell that occurs after pore formation. This release is reduced by the GAP activity of YopE. In order to study the role of LcrV, one has to circumvent the regulatory effect of LcrV on the synthesis of YopB and YopD. We observed here that this regulatory role of LcrV is lost in a yopQ mutant and hence we studied the role of LcrV in a yopQ mutant background. A lcrV, yopQ double mutant was deficient in pore formation while able to produce YopB and YopD. Pore formation was restored by the introduction of lcrV(+) but not yopQ(+) confirming that LcrV itself is directly required for pore formation. Bacteria secreting only YopB, YopD and LcrV could form pores, showing that YopB, YopD and LcrV are sufficient for pore formation provided they are secreted by the same bacterium. LcrV is not involved in secretion of YopB and YopD as suggested previously. Bacteria producing normal Ysc injectisomes, including the YscF needle but no translocators did not form pores, indicating that the needle is not sufficient by itself for pore formation, as was also suggested. yopN mutant bacteria formed needles and released BCECF even if they secreted the effectors. This observation suggests that many translocation pores are not filled in the absence of YopN and thus that YopN might form a link between the needle and the pore, guiding the effectors.


Subject(s)
Bacterial Proteins/genetics , Bacterial Proteins/physiology , Macrophages/metabolism , Macrophages/microbiology , Yersinia enterocolitica/genetics , Yersinia enterocolitica/pathogenicity , Animals , Antigens, Bacterial/genetics , Antigens, Bacterial/physiology , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/physiology , Biological Transport/genetics , Biological Transport/physiology , Cell Line , Fluoresceins/analysis , Fluoresceins/metabolism , Gene Deletion , Genes, Bacterial/genetics , L-Lactate Dehydrogenase/analysis , L-Lactate Dehydrogenase/metabolism , Membrane Proteins/genetics , Membrane Proteins/physiology , Mice , Pore Forming Cytotoxic Proteins , Yersinia enterocolitica/ultrastructure
3.
Infect Immun ; 71(1): 242-53, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12496172

ABSTRACT

All pathogenic Yersinia enterocolitica strains carry the pYV plasmid encoding the Ysc-Yop type III secretion (TTS) system, which operates at 37 degrees C. In addition, biovar 1B Y. enterocolitica strains possess a second, chromosomally encoded, TTS system called Ysa, which operates, at least in vitro, under low-temperature and high-salt (LTHS) conditions. Six open reading frames, sycB, yspB, yspC, yspD, yspA, and acpY, neighbor the ysa genes encoding the Ysa TTS apparatus. Here we show that YspA, YspB, YspC, and YspD are secreted by the Ysa TTS system under LTHS conditions. SycB is a chaperone for YspB and YspC and stabilizes YspB. YspB, YspC, and SycB share some similarity with TTS substrates and the chaperone encoded by the Mxi-Spa locus of Shigella flexneri and SPI-1 of Salmonella enterica. In addition, Ysa also secretes the pYV-encoded YopE under LTHS conditions, indicating that YopE is a potential effector of both Y. enterocolitica TTS systems. YspC could also be secreted by S. flexneri, but no functional complementation of ipaC was observed, which indicates that despite their similarity the Ysa and the Mxi-Spa systems are not interchangeable. When expressed from the yopE promoter, YspB and YspC could also be secreted via the Ysc injectisome. However, they could not form detectable pores in eukaryotic target cells and could not substitute for YopB and YopD for translocation of Yop effectors.


Subject(s)
Bacterial Outer Membrane Proteins/chemistry , Bacterial Proteins/chemistry , Molecular Chaperones/chemistry , Yersinia enterocolitica/metabolism , Animals , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biological Transport , Cell Line , Chromosomes, Bacterial/genetics , Gene Expression Regulation, Bacterial , HeLa Cells , Humans , Macrophages , Mice , Molecular Chaperones/genetics , Molecular Chaperones/metabolism , Molecular Sequence Data , Sequence Analysis, DNA , Substrate Specificity , Yersinia enterocolitica/genetics , Yersinia enterocolitica/pathogenicity
4.
J Bacteriol ; 184(12): 3214-23, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12029037

ABSTRACT

The Yop virulon enables extracellularly located Yersinia, in close contact with a eukaryotic target cell, to inject bacterial toxic proteins directly into the cytosol of this cell. Several Ysc proteins, forming the Yop secretion apparatus, display homology with proteins of the flagellar basal body. To determine whether this relationship could extend to the regulatory pathways, we analyzed the influence of flhDC, the master regulatory operon of the flagellum, on the yop regulon. In an flhDC mutant, the yop regulon was up-regulated. The transcription of virF and the steady-state level of the transcriptional activator VirF were enhanced. yop transcription was increased at 37 degrees C and could also be detected at a low temperature. Yop secretion was increased at 37 degrees C and occurred even at a low temperature. The Ysc secretion machinery was thus functional at room temperature in the absence of flagella, implying that in wild-type bacteria, FlhD and/or FlhC, or the product of a gene downstream of flhDC, represses the yop regulon. In agreement with this notion, increased expression of flhDC in wild-type bacteria resulted in the oversecretion of flagellins at room temperature and in decreased Yop secretion at 37 degrees C.


Subject(s)
Bacterial Outer Membrane Proteins/metabolism , DNA-Binding Proteins/genetics , Gene Deletion , Trans-Activators/genetics , Up-Regulation , Virulence Factors , Yersinia enterocolitica/metabolism , Bacterial Outer Membrane Proteins/genetics , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , DNA-Binding Proteins/metabolism , Escherichia coli Proteins , Gene Expression Regulation, Bacterial , Genetic Complementation Test , Operon , Regulon , Trans-Activators/metabolism , Yersinia enterocolitica/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...